Background Cutaneous immune-related adverse events (cirAEs) are a common sideeffect of immune checkpoint inhibitors (ICIs). However, prior work examining these toxicities in detail has considered only the fraction of events evaluated by dermatologists. Associations between dermatology referral, cirAE treatment and survival outcomes remain underexplored across care settings. Objectives To comprehensively categorize cirAE patterns among all patients treated with immunotherapy at our institution, and to evaluate: (i) the effect of dermatology referral on cirAE treatment and (ii) the impact of cirAE treatment on survival. Methods This was a retrospective cohort analysis of patients with cancer who initiated ICI therapy between 1 January 2016 and 8 March 2019 and developed one or more cirAEs, as screened for using International Classification of Diseases 10th revision codes and confirmed via manual chart review (n = 358). All relevant information documented prior to 31 March 2020 was included. Results CirAEs evaluated by dermatologists were significantly more likely to be treated than cirAEs that were not referred (odds ratio 6Á08, P < 0Á001). Patients who received any cirAE treatment had improved progression-free survival [hazard ratio (HR) 0Á59, P = 0Á001] and overall survival (HR 0Á58, P = 0Á007) compared with those who did not. Conclusions CirAEs evaluated by dermatologists were significantly more likely to be treated than cirAEs that were not referred, and patients who received any treatment for a cirAE had improved survival outcomes.What is already known about this topic?• Cutaneous immune-related adverse events (cirAEs) are common among patients on immune checkpoint inhibitor (ICI) therapy, occurring in up to one-third of ICI monotherapy recipients.• Despite the prevalence of cirAEs, the relationships between dermatology referral, cirAE treatment and survival outcomes remain underexplored.What does this study add?• CirAEs evaluated by dermatologists were significantly more likely to be treated than cirAEs that were not referred, and patients who received treatment had improved survival.• Our findings underscore the vital role of dermatologists in oncological care and suggest that closer collaboration between oncologists and dermatologists may be valuable in supporting comprehensive cirAE treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.